Global After gaining its first global approval in Indonesia, Takeda’s dengue fever vaccine, Qdenga, recently got a green light from the European Commission (EC) to market the vaccine in Europe, laying the foundation for further approvals in dengue-endemic regions like Latin America. We are one step closer to achieving our aspiration…
Global Insights from US President Joe Biden’s chief medical adviser, Anthony Fauci, who served on the White House Coronavirus Task Force at the height of the pandemic, on the end of COVID-19, the danger of China’s recent surge in cases, preparedness for future pandemics, and the misinformation in the US that…
Global Over the past year, PharmaBoardroom has spoken to pharma executives the world over, collecting unique perspectives from all sides of the industry. Here are the ten most-read interviews of 2022 that range from conversations with one of Korea’s top CDMOs to the American generics association and the Italian regulatory agency,…
Global PharmaBoardroom’s network of thought leaders continued to provide some of our top content in 2022, covering topics such as Africa’s first integrated drug discovery platform, Chinese vaccine exports, inequities in US healthcare, antimicrobial pollution and new pharmaceutical legislation in Europe. See our dedicated op-ed page for all of the year’s contributions…
Global CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in the company’s history, and the FDA approval of its gene therapy for haemophilia B. Newly appointed CEO Paul McKenzie takes…
UK Bernard Ross, a serial entrepreneur with more than 20 years’ senior experience at private and public board level across multiple industries, looks ahead to 2023 and highlights five key trends to watch in the medtech space. With the COVID-19 pandemic having fast-forwarded the adoption of medical device innovations to solve…
USA Clinical trial diversity not only allows for a better understanding of the safety and efficacy of new therapies in population subgroups but also plays a significant role in reducing health inequities. In conversation with PharmaBoardroom, outgoing president and global chief executive of the Drug Information Association (DIA) Barbara Lopez Kunz,…
USA Reflecting on a transformational decade at the helm of the Drug Information Association (DIA), Barbara Lopez Kunz highlights some of the key achievements and most significant trends that have emerged during her tenure. Lopez Kunz points to the DIA’s evolution into a truly global knowledge-sharing platform, the COVID-19 pandemic’s impact…
Global After a turbulent five-year tenure, Kare Schultz will be stepping down as the Israeli generics giant ‘s CEO and former Sandoz chief Richard Francis will take over in January. Francis, who brings his vast industry experience at companies like Sandoz and Biogen to the role, will inherit a number of…
Global British pharma exec Paul Hudson joined the French pharma giant in 2019 and soon brought forward a new strategy aimed at focusing on first-in-class or best-in-class drugs and offloading the firm’s underperforming businesses. Since then and after weathering COVID-19 vaccine race defeat, Hudson has seen Sanofi through some significant wins…
Global After an almost 20-year career in Big Pharma culminating in a role as president of AstraZeneca UK, Lisa Anson took the leap into the biotech world to lead what at the time was an ailing business, UK-based Redx Pharma. Having transformed Redx into the thriving biotech that it is today,…
Global The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this year’s edition that the 20 companies surveyed have firmly responded to access issues exposed by COVID-19. GSK remains at the…
See our Cookie Privacy Policy Here